AMELIORATIVE EFFECTS OF SORAFENIB ON THIOACETAMIDE-INDUCED HEPATOCELLULAR CARCINOMA IN A RAT MODEL Yomna Elleithi1, Mohamed N. Amin1, Amal El-Gayar1 1Biochemistry Department, Faculty of Pharmacy, Mansoura University
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and is a leading cause of cancer-related death worldwide. HCC is also the fourth common cancer in Egypt. Sorafenib (Nexavar) is an orally active multikinase inhibitor that is approved as first line treatment of advanced stage HCC. In the current study, HCC was induced in male spargue-dawely rats by twice daily injection of thioacetamide (TAA) with the dose 200 mg/kg body weight for 16 consecutive weeks. To assess the therapeutic effect of sorafenib histopathological examination of liver sections was carried out along with biochemical testing and alpha-feto protein (AFP) serum levels. The results showed that sorafenib administration succeeded to significantly (P<0.05) reduce liver/body weight ratio & serum AFP levels. This was in agreement with the histopathological scoring and the improvement in the hepatic function. Further studies on this model should be conducted to evaluate the effect of different combination of drugs with sorafenib.